Newer combination antifungal therapies for invasive aspergillosis

Medical Mycology

Volumn 49, Issue SUPPL. 1, 2011, Pages

  Steinbach, William J ^a,b   Juvvadi, Praveen R ^a   Fortwendel, Jarrod R ^a,b   Rogg, Luise E ^a  

^a Division of Pediatric Infectious Diseases   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antifungal; aspergillosis; Aspergillus; calcineurin; combination

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CALCINEURIN; CALCINEURIN A; CALCINEURIN INHIBITOR; CASPOFUNGIN; CYCLOSPORIN A; ECHINOCANDIN; FLUCONAZOLE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; TACROLIMUS; TRIAZOLE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIMICROBIAL THERAPY; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DISEASE MODEL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; ENZYME ACTIVATION; ENZYME INHIBITION; GUINEA PIG; HUMAN; INFECTION PREVENTION; INVASIVE ASPERGILLOSIS; MONOTHERAPY; NONHUMAN; OVERALL SURVIVAL; PROTEIN FUNCTION; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC MYCOSIS;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; CALCINEURIN; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HSP90 HEAT-SHOCK PROTEINS; HUMANS;

ANIMALIA; ASPERGILLUS;

EID: 79952645830     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2010.499374     Document Type: Conference Paper

References (26)

1. Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of ampho-tericin B alone and combined with f ucytosine in the treatment of cryptococcal meningitis. N Engl J Med 1979; 301: 126-128.
2. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000; 30: 696-709.
3. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415. (Pubitemid 34851833)
4. Lewis RE, Kontoyiannis DP. Rationale for combination antifungal therapy. Pharmacotherapy 2001; 21: 149S-164S. (Pubitemid 32734077)
5. Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. Efficacy of caspo-fungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002; 46: 2564-2568. (Pubitemid 34793464)
6. MacCallum DM, Whyte JA, Odds FC. Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. Antimicrob Agents Chemother 2005; 49: 3697-3701. (Pubitemid 41233020)
7. Ibrahim AS, Gebremariam T, French SW, Edwards JEJ, Spellberg B. The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis. J Anti-microb Chemother 2010; 65: 289-292.
8. Caillot D, Thiébaut A, Herbrecht R, et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer 2007; 110: 2740-2746. (Pubitemid 350250344)
9. Perea S, Gonzalez G, Fothergill A, et al. In vitro interaction of caspo-fungin acetate with voriconazole against clinical isolates of Aspergil-lus spp. Antimicrob Agents Chemother 2002; 4: 3039-3041.
10. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39: 797-802. (Pubitemid 39244292)
11. Viscoli C. Combination therapy for invasive aspergillosis. Clin Infect Dis 2004; 39: 803-805. (Pubitemid 39244293)
12. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillo-sis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-360. (Pubitemid 351265310)
13. Klee CB, Crouch TH, Krinks MH. Calcineurin: a calcium- and calmodulin-binding protein of the nervous system. Proc Nat Acad Sci 1979; 76: 6270-6273. (Pubitemid 10163382)
14. Fox DS, Heitman J. Good fungi gone bad: the corruption of icalcineu-rin. Bioessays 2002; 24: 894-903. (Pubitemid 35197585)
15. Steinbach WJ, Reedy JL, Cramer RA, Jr., Perfect JR, Heitman J. Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections. Nature Rev Microbiol 2007; 5: 418-430. (Pubitemid 46780079)
16. Clipstone NA, Crabtree GR. Identification of calcineurin as a key signaling enzyme in T-lymphocyte activation. Nature 1992; 357: 695-697.
17. Hofiin JM, Potasman I, Baldwin JC, et al. Infectious complications in heart transplant recipients receiving cyclosporine and corticosteroids. Ann Int Med 1987; 106: 209-216.
18. Singh N, Avery RK, Munoz P, et al. Trends in risk prof les for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Inf Dis 2003; 36: 46-52. (Pubitemid 36099096)
19. Steinbach WJ, Cramer Jr RA, Perfect BZ, et al. Calcineurin controls growth, morphology, and pathogenicity in Aspergillus fumigatus. Eukaryotic Cell 2006; 5: 1091-1103. (Pubitemid 44100707)
20. Cramer RAJ, Perfect BZ, Pinchai N, et al. Calcineurin target CrzA regulates conidial germination, hyphal growth, and pathogenesis of Aspergillus fumigatus. Eukary Cell 2008; 7: 1085-1097. (Pubitemid 351969323)
21. Kontoyiannis D, Lewis R, Osherov N, Albert N, May G. Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species. Antimicrob Agents Chemother 2003; 51: 313-316. (Pubitemid 36231150)
22. Steinbach WJ, Cramer RA, Jr., Perfect BZ, et al. Calcineurin inhibition or mutation enhances cell wall inhibitors against Aspergillus fumigatus. Antimicrob Agents Chemother 2007; 51: 2979-2981. (Pubitemid 47206239)
23. Fortwendel JR, Juvvadi PR, Pinchai N, et al. Differential effects of inhibiting chitin and 1,3-{beta}-D-glucan synthesis in Ras and calcineu-rin mutants of Aspergillus fumigatus. Antimicrob Agents Chemoth 2009; 53: 476-482.
24. Fortwendel JR, Juvvadi PR, Perfect BZ, et al. Transcriptional regulation of chitin synthases by calcineurin controls paradoxical growth of Aspergillus fumigatus in response to caspofungin. Antimicrob Agents Chemother 2010; 54: 1555-1563.
25. Cowen LE, Lindquist S. Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 2005; 309: 2185-2189. (Pubitemid 41396062)
26. Cowen LE, Singh SD, K ö hler JR, et al. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Nat Acad Sci 2009; 106: 2818-2823.